Cystadenocarcinoma, Serous
"Cystadenocarcinoma, Serous" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A malignant cystic or semicystic neoplasm. It often occurs in the ovary and usually bilaterally. The external surface is usually covered with papillary excrescences. Microscopically, the papillary patterns are predominantly epithelial overgrowths with differentiated and undifferentiated papillary serous cystadenocarcinoma cells. Psammoma bodies may be present. The tumor generally adheres to surrounding structures and produces ascites. (From Hughes, Obstetric-Gynecologic Terminology, 1972, p185)
| Descriptor ID |
D018284
|
| MeSH Number(s) |
C04.557.470.200.025.480.240 C04.557.470.590.480.240
|
| Concept/Terms |
Cystadenocarcinoma, Serous- Cystadenocarcinoma, Serous
- Cystadenocarcinomas, Serous
- Serous Cystadenocarcinoma
- Serous Cystadenocarcinomas
|
Below are MeSH descriptors whose meaning is more general than "Cystadenocarcinoma, Serous".
Below are MeSH descriptors whose meaning is more specific than "Cystadenocarcinoma, Serous".
This graph shows the total number of publications written about "Cystadenocarcinoma, Serous" by people in this website by year, and whether "Cystadenocarcinoma, Serous" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2006 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2009 | 1 | 0 | 1 |
| 2010 | 2 | 0 | 2 |
| 2011 | 2 | 1 | 3 |
| 2013 | 2 | 0 | 2 |
| 2014 | 2 | 0 | 2 |
| 2015 | 4 | 0 | 4 |
| 2016 | 3 | 0 | 3 |
| 2017 | 1 | 2 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 1 | 2 |
| 2020 | 4 | 0 | 4 |
| 2021 | 1 | 1 | 2 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cystadenocarcinoma, Serous" by people in Profiles.
-
Ovarian cancer metastasis: Looking beyond the surface. Cancer Cell. 2024 Oct 14; 42(10):1631-1636.
-
Innovations in Rare Gynecologic Cancer: Melanoma, Neuroendocrine, and Low-Grade Serous Ovarian. Am Soc Clin Oncol Educ Book. 2024 Jun; 44(3):e431818.
-
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70?years and over. Gynecol Oncol. 2024 08; 187:221-226.
-
Diagnosis Shift in Site of Origin of Tubo-Ovarian Carcinoma. Obstet Gynecol. 2024 May 01; 143(5):660-669.
-
Validation and interpretation of Pan-TRK immunohistochemistry: a practical approach and challenges with interpretation. Diagn Pathol. 2024 Jan 10; 19(1):10.
-
Current Laboratory Testing Practices for Assessment of ERBB2/HER2 in Endometrial Serous Carcinoma and Colorectal Carcinoma. Arch Pathol Lab Med. 2023 10 01; 147(10):1148-1157.
-
Low-grade serous ovarian cancer: expert consensus report on the state of the science. Int J Gynecol Cancer. 2023 09 04; 33(9):1331-1344.
-
Proteogenomic analysis of chemo-refractory high-grade serous ovarian cancer. Cell. 2023 08 03; 186(16):3476-3498.e35.
-
HER2/ ERBB2 Immunohistochemical Expression and Copy Number Status in Ovarian Mucinous Tumors. Int J Gynecol Pathol. 2024 Mar 01; 43(2):134-139.
-
Characterizing morphologic subtypes of high-grade serous ovarian cancer by CT: a retrospective cohort study. Int J Gynecol Cancer. 2023 06 05; 33(6):937-943.